Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132035 | 0.78 | MAPT (0.41) | APPMAPTTHRBHPGDALOX15 | |
| SCHEMBL19940000 | 0.65 | — | — | |
| SCHEMBL20271280 | 0.65 | APP (0.37) | APPMAPTHPGDALOX15SNCA | |
| SCHEMBL8538111 | 0.65 | HPGD (0.38) | APPMAPTHPGDALOX15TSHR | |
| SCHEMBL29440260 | 0.63 | ALDH1A1 (0.52) | APPMAPTTHRBHPGDALOX15 | |
| SCHEMBL8400468 | 0.63 | LMNA (0.45) | MAPTTHRBHPGDALOX15TSHR | |
| SCHEMBL13736031 | 0.63 | ALDH1A1 (0.52) | APPMAPTTHRBHPGDALOX15 | |
| SCHEMBL11329976 | 0.63 | HSD17B10 (0.40) | MAPTHPGDALOX15TSHRCASP1 | |
| SCHEMBL10686717 | 0.62 | KDM4E (0.35) | MAPTHPGDALOX15RECQLHSD17B10 | |
| SCHEMBL29104759 | 0.62 | ALDH1A1 (0.50) | APPMAPTTHRBHPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120116191-A1 | USE OF AN EQUILIBRIUM INTRAVASCULAR SENSOR TO ACHIEVE TIGHT GLYCEMIC CONTROL | GLUMETRICS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20100274110-A1 | OPTICAL DETERMINATION OF PH AND GLUCOSE | GluMetrics, Inc (US) | 2010-10-28 | — | — | US | disclosed |
| US-7417164-B2 | Fluorescent dyes for use in glucose sensing | GLUMETRICS INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080027245-A1 | FLUORESCENT DYES FOR USE IN GLUCOSE SENSING | GLUMETRICS INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027245-A1 | FLUORESCENT DYES FOR USE IN GLUCOSE SENSING | SLC2A4, SLC2A8, SLC2A1 | APP 2611/4885MAPT 3889/4885THRB 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.